Neurodegenerative diseases
This page brings together the European Medicines Agency's (EMA) latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis.
It lists the following:
- The newest and most recently updated medicines authorised for the treatment of neurodegenerative diseases in the European Union
- EMA's latest news announcements related to neurodegenerative diseases
- EMA's events on topics related to neurodegenerative diseases
We are currently unable to display the new and recently updated medicines authorised for neurodegenerative diseases due to a technical error. We are working to resolve the issue as soon as possible. We apologise for any inconvenience caused.
Latest news
EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting.
22 March 2024
EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting.
23 February 2024
EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease that causes muscles to become weak and leads to paralysis. Qalsody (tofersen) is indicated for the treatment of adults with ALS, who have a...
23 February 2024
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its December 2023 meeting.
15 December 2023
Events of interest
Currently, we have no events for this therapeutic area.
EMA Custom Webtools Rating widget: Hidden by field_ema_hide_rating for this node.